Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Vaccinex, Aridis Launch August's First US IPOs As The Summer Simmer Slows

Executive Summary

The summer slowdown finally seems to have hit the US biopharma IPO market; after a hot July with nine offerings, there were just two during the first half of August. Also, Zogenix leads recent follow-ons with a $312m offering; venture capital planted in UK biotechs – Orchard and Blueberry.

Advertisement

Related Content

Keeping Track: Poteligeo, Onpattro, Galafold And Annovera Approved; Selinexor Submitted
RedHill's Antibiotic Approach For Crohn's Shows Promise, Caveats Remain
Arix Taps Australia's 'Undervalued' Pharmaxis As First VIPE, More Planned
Laquinimod Disappoints Again, This Time In Huntington's Disease
Zogenix' ZX008 Emerges As Strong Contender In Rare Epilepsy
14 Approvals To Look Out For In Q3
Deal Watch: Gilead And Spring Bank Set Second Trial Collaboration In HBV
Finance Watch: Cash Flows Into Public Biopharmas, Including IPOs; Atlas Raises $350m VC Fund
Janssen Enriches Crohn's Portfolio In Deal For Protagonist's Oral IL-23 Inhibitor
Blueberry Therapeutics Ltd.

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123698

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel